Drug intelligence / Profile preview

RV03

Development stage: Unknown
Lead developer: Intellect Neurosciences
Modality: Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

**RV03** is a preclinical, first-in-class chimeric peptide vaccine developed by Intellect Neurosciences. It is designed as a dual-acting therapeutic vaccine that induces an immune response against both beta amyloid and delta tau, key pathological proteins implicated in Alzheimer's disease. This approach aims to address amyloid plaques and tau tangles simultaneously using the RECALL-VAX™ technology platform.[1][3]

Targets

pE-Aβ (Pyroglutamylated amyloid-β)TauC3 (Tau truncated at Asp421)

Beyond the preview

Go deeper on RV03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV03.

Explore the full profile